Suven Pharmaceuticals share price rises 5% on announcement regarding CDMO firm Sapala Organics acquisition

livemint.com:

Suven Pharmaceuticals share price gained more than 5% in the morning trades on Friday post its announcement regarding acquisition of Hyderabad based CDMO firm Sapala Organics on Thursday post market hours.Suven Pharma share price that opened at ₹695.00, higher than previous close of ₹667.95, gained further more to ₹705 levels in the NSE, marking gains of more than 5%.Suven Pharmaceuticals announcement on the exchanges said that that it has executed definitive agreements on June 13, 2024, for acquiring 100% of equity shares (on a fully diluted basis) in Sapala Organics Private Limited.Also Read- Kotak Institutional raises target price for Adani Ports and SEZ to ₹1,650, says outperformance can continue for longThe Hyderabad based Sapala Organics is contract development and manufacturing organizations (CDMO) that is focused on Oligo drugs and nucleic acid building blocks including Phosphoramidites & Nucleosides, drug delivery compounds (including GalNAc), Pseudouridine, amongst others.Suven Pharmaceuticals in its presentation highlighted that Sapala Organics sales stood at ₹67 Crore with more than 45% Ebitda margins in FY24. Ebitda stands for Earnings before, Interest, Tax, Depreciation and amortisation.Sapala Organics has a customer-base across the US, European Union and Japan; partnering on their New Chemical Entity (NCE) programs across project lifecycle.

Sapala Organics has a strong Japan presence as its sales from Japan averaged around 20% of FY21-24e, as per the presentation. Nucleic acid & Oligo building blocks market is expected to grow 18-20% CAGR (compound annual growth) over FY24-29 to $1800 million.Also Read-Ambuja Cements share price jumps 3% as Penna Cement acquisition seem value accretive; analysts bullish on